Visualitza per autor "Hollebecque, Antoine"
Ara mostrant els elements 1-5 d 5
-
Clinical activity of CC-90011, an oral, potent, and reversible LSD1 inhibitor, in advanced malignancies
Hollebecque, Antoine; Salvagni, Stefania; Plummer, Ruth; Niccoli, Patricia; Capdevila Castillon, Jaume; Curigliano, Giuseppe (Wiley, 2022-09-01) -
First-in-human, dose-escalation, phase 1 study of anti-angiopoietin-2 LY3127804 as monotherapy and in combination with ramucirumab in patients with advanced solid tumours
Martín Liberal, Juan Jesús; Hollebecque, Antoine; Jungels, Christiane; Martin-Romano, Patricia; Rodon Ahnert, Jordi; Aftimos, Philippe (Springer Nature, 2020-10) -
Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer
Hollebecque, Antoine; Varghese, Anna; Borazanci, Erkut; Macarulla Mercadé, Teresa; Oh, Do-Youn; Melisi, Davide; Calvo, Emiliano (BMJ Publishing Group, 2021-03-09) -
Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial
Naumann, R. Wendel; Hollebecque, Antoine; Meyer, Tim; Devlin, Michael-John; Oaknin Benzaquen, Ana Mazaltob; Kerger, Joseph (American Society of Clinical Oncology, 2019-11-01) -
Trifluridine/tipiracil in combination with oxaliplatin and either bevacizumab or nivolumab in metastatic colorectal cancer: a dose-expansion, phase I study
Bordonaro, R.; Calvo, A.; Auriemma, A.; Hollebecque, Antoine; Rubovszky, G.; Saunders, M. P.; Argilés Martinez, Guillem; Tabernero Caturla, Josep (Elsevier, 2021-10)